ERBB2 and neoplasm: While most target proteins on solid cancer cells are also expressed by healthy cells, such as ErbB2, the binding domain was re-engineered in favor of a low affinity to reduce the binding to the low antigen expressing healthy cells and finally to reduce the on-target off-tumor toxicity [8].